Key Takeaways
- Morgan Stanley cut Novo Nordisk’s rating from Equal-weight to Underweight while maintaining a 250 Danish crown price target
- Shares dropped approximately 2.4% during morning trading in Copenhagen
- The company derives 75% of its revenue from semaglutide, which faces patent expiration in the early-to-mid 2030s
- Analysts project 2-3% revenue and EBIT expansion for 2027, trailing the European pharmaceutical sector average
- Morgan Stanley identifies few positive catalysts before the company’s September 21 capital markets day
Novo Nordisk shares fell sharply after [[LINK_START_1]]Morgan Stanley[[LINK_END_1]] issued a downgrade, shifting its stance to Underweight. The Copenhagen market reacted with a 2.4% decline in the stock price.
The research team headed by Thibault Boutherin expressed concerns that the stock’s present valuation fails to account for its modest medium-term growth trajectory. Their 250 Danish crown price objective suggests potential downside exceeding 10% from recent closing levels.
The primary issue centers on semaglutide, the compound behind Ozempic and Wegovy. This ingredient generated 75% of Novo’s revenue in 2026.
This heavy dependence creates vulnerability in the early-to-mid 2030s, when patent protection for semaglutide expires across Europe and the United States. Morgan Stanley’s projections indicate the drug will still represent 59% of total sales in 2031, precisely when exclusivity loss becomes material.
Underwhelming Growth Trajectory
The investment bank anticipates 2-3% expansion in both revenue and EBIT for 2027, aligning with market consensus. However, between 2027 and 2030, Morgan Stanley forecasts just a 4% compound annual growth rate for both metrics.
This outlook falls short when measured against the bank’s expectations for the European pharmaceutical industry, which projects 4% revenue growth and 7% EBIT expansion during the identical timeframe.
While Morgan Stanley acknowledges that Novo’s oral obesity portfolio could achieve $10 billion in annual sales by 2031, the analysts cautioned that this performance “will not be enough to offset pricing and competitive headwinds.”
A Morgan Stanley proprietary survey covering 200 primary care physicians revealed increasing GLP-1 medication adoption overall. Yet the data also indicated Novo will surrender market share during the next 18 months, as Eli Lilly’s existing products and its anticipated retatrutide launch in 2027 capture additional ground.
Valuation Gap and Upcoming Investor Event
From a valuation perspective, Novo currently trades at 12.5 times projected 2027 earnings. This represents a 7% discount compared to European large-cap pharmaceutical companies, yet commands a 35% premium versus global competitors confronting comparable patent challenges, including Sanofi and GSK.
Morgan Stanley highlighted this disparity particularly, emphasizing the premium appears “more pronounced” relative to GSK’s 10x multiple and Sanofi’s 8x multiple.
The company has scheduled its capital markets day for September 21. Morgan Stanley anticipates management will confirm its oral obesity strategic direction and offer progress reports on business development initiatives spanning MASH and chronic kidney disease.
The research team indicated they anticipate “limited scope for major announcements” during the presentation.
A potential positive scenario for shareholders would emerge if oral obesity therapies secure greater patient market penetration than currently projected and demonstrate stronger resilience against competitive pressures and generic alternatives than modeled.
Morgan Stanley’s rating change positions the stock in Underweight classification, signaling the analysts anticipate underperformance relative to sector peers moving forward.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
